KNSA Q4 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$33M

Net Income

-$32M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$26M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$255M

Total Liabilities

$29M

Stockholders' Equity

$225M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$33M	-$44M	+26.2%
Net Income	-$32M	-$43M	+25.3%